The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced its brain cancer imaging drug, Pixclara, has won approval from the US FDA—making it the first FET-PET imaging drug cleared for use in glioma and expanding Telix’s precision medicine portfolio.

What did Telix Pharmaceuticals report?

• FDA approved Pixclara® (floretyrosine F 18), for imaging gliomas (brain cancer) in adult and paediatric patients
• Pixclara is the first FDA-approved FET-PET imaging drug for glioma
• Pixclara’s approval addresses a significant unmet need in US brain cancer diagnostics
• Product expansion reinforces Telix’s position in precision diagnostics and targeted radiopharmaceutical “theranostics”

What else do investors need to know?

Pixclara is the only FDA-approved radiopharmaceutical imaging drug specifically for glioma, a difficult-to-treat brain cancer representing around 24,000 new cases annually in the US. The new drug is indicated for adults and children as young as one month old and is expected to support better treatment decision-making for both clinicians and patients.

The approval also makes Pixclara eligible for widespread clinical use. FET-PET imaging has been recommended in various international guidelines, but until now, there was no FDA-approved product available in the United States. Telix already has other FDA-approved imaging offerings and is working on advancing late-stage therapies across multiple cancers.

What did Telix Pharmaceuticals management say?

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said:

FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.

What’s next for Telix Pharmaceuticals?

Telix says Pixclara is already the subject of a Phase 3 trial for diagnosis in additional brain conditions, with potential expansion to brain metastases. The company continues to leverage its global diagnostics platform and late-stage radiopharmaceutical pipeline to target market leadership in both imaging and treatment for several high-need cancers.

Telix’s broader pipeline includes late-stage assets in prostate, kidney, and glioblastoma cancers, with a focus on bringing further precision medicine products to both existing and new markets worldwide.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have risen 12%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug appeared first on The Motley Fool Australia.

More reading

• Forget CSL shares. 3 ASX healthcare stocks with bigger upside
• CSL led the ASX healthcare shares rebound. Can it continue?
• 4 high conviction ASX stock picks from Canaccord Genuity
• Telix shares are up 98%: Is there more upside to come?
• Telix shares are tumbling. Is the stock finally at fair value?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Cleanaway Waste Management Ltd (ASX: CWY) share price is in focus following its latest update on the proposed EQT Infrastructure acquisition. EQT has restated its intent to proceed without any negative changes to its initial indicative price, giving shareholders renewed confidence in the ongoing scheme discussions.

What did Cleanaway Waste Management report?

• EQT Infrastructure confirmed nothing in its due diligence would cause it to withdraw or reduce its indicative proposal.
• No less favourable terms are proposed for Cleanaway shareholders.
• The offer consideration remains at least at the previously indicated level.
• The hard exclusivity period under the Transaction Process Deed has ended as planned.
• Both parties are working toward an implementation deed but no binding agreement has been reached yet.

What else do investors need to know?

EQT Infrastructure has finished its agreed exclusivity period for reviewing Cleanaway, but remains engaged and positive about progressing the transaction. The proposal is still indicative and non-binding, meaning there is no guarantee it will result in a formal offer.

Shareholders are not required to take any action currently. Cleanaway’s board has assured investors that they will provide further updates as developments occur. The Board’s proactive communication helps keep everyone in the loop on this potential change in ownership.

What’s next for Cleanaway Waste Management?

The next key step will be finalising due diligence and entering into an implementation deed—if terms can be agreed—so shareholders can consider a definitive proposal. Cleanaway continues operating as usual, maintaining its commitment to service, sustainability, and shareholder value.

With the deal still unconfirmed, investors should watch future announcements closely for any advances, revised offers, or changes in EQT’s intentions.

Cleanaway Waste Management share price snapshot

Over the past 12 months, Cleanaway shares have declined 9%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Cleanaway Waste Management provides EQT bid update appeared first on The Motley Fool Australia.

More reading

• 40 ASX shares with ex-dividend dates next week
• Cleanaway FY26: earnings rise, dividend up, takeover bid in play

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Wesfarmers Ltd (ASX: WES) shares have been a solid choice for growing wealth over the last several years. We’re going to consider whether the company can deliver good returns from here.

Wesfarmers is best known as the owner of Bunnings Group (which includes Beaumont Tiles) and Kmart Group (which includes Anko and Target).

The company has several businesses in its portfolio, including chemicals, energy, a fertiliser business called WesCEF, and its healthcare segment, which includes Priceline and InstantScripts.

The company recently reported its FY26 result, which gave investors insights into its performance and helps figure out what the investment’s underlying value.

FY26 earnings recap

For the 12 months to 30 June 2026, the business reported revenue growth of 3.4% to $47.3 billion.

Overall, Bunnings Group revenue grew 4.1% to $20.4 billion, Kmart Group revenue rose 2.8% to $11.75 billion, WesCEF revenue increased 5.9% to $3.1 billion, Officeworks revenue rose 3.7% to $3.7 billion, and healthcare revenue grew 9.1% to $6.5 billion.

Turning to profitability, underlying operating profit (EBIT) rose 7.3% to $4.5 billion, and underlying net profit increased 8.3% to $2.87 billion.

In terms of divisional earnings, Bunnings Group earnings before tax (EBT) rose 5.1% to $2.45 billion, Kmart Group EBT climbed 6% to $1.1 billion, WesCEF EBT increased 18.5% to $473 million, Officeworks EBT declined 22.2% to $165 million and the Wesfarmers healthcare division EBT increased 18.8% to $76 million.

Given the challenging retail conditions, I think the company delivered an impressive performance.

Its trading update was promising, with commentary suggesting that sales growth has continued for Kmart and Bunnings in the first seven weeks of FY27.

Given its market-leading position in affordable hardware and general merchandise, I think the business is well positioned for the current economic climate.

What could happen with a $10,000 investment in Wesfarmers shares?

According to CMC Invest, there have been 11 analyst ratings on the company within the last three months.

Of those 11 expert ratings, the average price target is $78.13. A price target is where analysts think the (Wesfarmers) share price will go in 12 months from the time of the investment call.

The average price target of $78.13 implies the Wesfarmers share price could rise by 7.3% over the next year. Therefore, a $10,000 investment could grow to $10,700, which would be solid return, in my opinion.

On top of that, the business could pay an annual dividend per share of $2.40 in FY27, according to CMC Invest. That could translate into a grossed-up dividend yield of 4.7%, including franking credits.

Overall, investors in Wesfarmers could see a $10,000 investment turn into more than $11,000 of total wealth within the next 12 months. That could be a solid investment, but there could be even better ASX share buys available.

The post By September 2027, Wesfarmers shares could turn $10,000 into… appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Corporate Travel Management, Wesfarmers, Fortescue shares
• How to build a superannuation portfolio generating $50,000 a year
• With no savings at 50, I’d follow Warren Buffett’s approach to build wealth
• 3 reasons why the Wesfarmers share price is a buy
• How much is needed in superannuation to target a $70,000 annual passive income?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.